<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="43053">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02545868</url>
  </required_header>
  <id_info>
    <org_study_id>BN29739</org_study_id>
    <secondary_id>2015-001357-32</secondary_id>
    <nct_id>NCT02545868</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This multicenter, randomized, open-label study will evaluate the immune response to vaccines
      (tetanus toxoid [TT], 23-valent pneumococcal polysaccharide vaccine [23-PPV], influenza
      vaccine, and keyhole limpet hemocyanin [KLH]) after administration of a dose of ocrelizumab
      (OCR) in participants with relapsing multiple sclerosis (RMS).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in With Positive Response to TT Vaccine Measured 8 Weeks After TT Vaccine</measure>
    <time_frame>8 weeks after TT vaccine</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in With Positive Response to TT Vaccine Measured 4 Weeks After TT Vaccine</measure>
    <time_frame>4 weeks after TT vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in With Positive Response to 23-PPV Measured 4 Weeks After 23-PPV</measure>
    <time_frame>4 weeks after 23-PPV</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in With KLH Immunization Measured 4 Weeks After KLH Vaccine</measure>
    <time_frame>4 weeks after KLH vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in With Positive Response to Pneumococcal Conjugate Booster Measured 4 Weeks After the Booster 13-PCV</measure>
    <time_frame>4 weeks after the booster 13-PCV</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in With Influenza Vaccine Response Measured 4 Weeks After the Influenza Vaccine</measure>
    <time_frame>4 weeks after the influenza vaccine</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <arm_group>
    <arm_group_label>OCR + Vaccines</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will first receive ocrelizumab (OCR) on Day 1 and Day 15, and 12 weeks post-OCR treatment will receive immunization with TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaccines + No Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive immunization with TT-containing adsorbed vaccine, 23-PPV, influenza vaccine, and repeated administration with KLH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>23-valent PPV</intervention_name>
    <description>The 23-valent PPV will be administered at 112 days after the first OCR administration or at Day 28 (for participants not receiving OCR).</description>
    <arm_group_label>OCR + Vaccines</arm_group_label>
    <arm_group_label>Vaccines + No Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Booster 13-PCV</intervention_name>
    <description>The booster 13-PCV will be administered on Day 140 for first subgroup of participants with OCR administration.</description>
    <arm_group_label>OCR + Vaccines</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Vaccine</intervention_name>
    <description>The influenza vaccine will be administered any time between days 84 and 140 (for second subgroup of participants with OCR administration) or any time between day 1 and 84 (for participants not receiving OCR).</description>
    <arm_group_label>OCR + Vaccines</arm_group_label>
    <arm_group_label>Vaccines + No Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>KLH Vaccine</intervention_name>
    <description>The KLH Vaccine will be administered at 84, 112, and 140 days after the first OCR administration or at Day 1, 28, and 56 (for participants not receiving OCR).</description>
    <arm_group_label>OCR + Vaccines</arm_group_label>
    <arm_group_label>Vaccines + No Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCR 300mg</intervention_name>
    <description>OCR 300 milligram (mg) intravenous infusion administered at Day 1 and Day 15.</description>
    <arm_group_label>OCR + Vaccines</arm_group_label>
    <other_name>RO4964913</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TT Vaccine</intervention_name>
    <description>An adsorbed TT-vaccine combined with diphtheria (tetanus-diphtheria [Td] or diphtheria and tetanus toxoid [DT]) or with diphtheria and acellular pertussis (diphtheria-tetanus-acellular pertussis [DTaP] or tetanus-diphtheria-acellular pertussis [Tdap]) will be administered at 84 days after the first OCR administration or at Day 1 (for participants not receiving OCR).</description>
    <arm_group_label>OCR + Vaccines</arm_group_label>
    <arm_group_label>Vaccines + No Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of RMS in accordance with the revised McDonald criteria

          -  Received at least 1 previous immunization against TT or tetanus and diphtheria
             (DT/Td) or tetanus, diphtheria, and acellular pertussis (DTaP/Tdap)

          -  Expanded disability status scale (EDSS) at baseline from 0 to 5.5 points, inclusive

          -  For sexually active participants with reproductive potential, use of reliable means
             of contraception

        Exclusion Criteria:

          -  Contraindications for or intolerance to oral or intravenous corticosteroids,
             including intravenous methylprednisolone, according to the country label

          -  Known presence of other neurologic disorders

          -  Treatment with any investigational agent within 24 weeks of screening or 5 half-lives
             of the investigational drug, whichever is longer, or treatment with any experimental
             procedure for multiple sclerosis (MS)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Cullman</city>
        <state>Alabama</state>
        <zip>35058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <state>Missouri</state>
        <zip>63017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willow Grove</city>
        <state>Pennsylvania</state>
        <zip>19090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordova</city>
        <state>Tennessee</state>
        <zip>38018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>September 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
